1789 TT

ScinoPharm Investor Conference

— 2025 03 13

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Overview of Business Operations

02 Business Update and Outlook

03 Financial Performance



Overview of Business Operations

I. Core business solid and growing. Moderate topline growth and superior bottom line growth

- In 2024, consolidated revenue reached US$106.11 million, 4% YOY increase. Revenue in NTD was 3,406 million, representing a 7% YOY growth.
- Net profit after tax was NT$339 million, up 18% compared to 2023
- Both ScinoPharm Taiwan and ScinoPharm Changshu operations are progressing steadily, each achieving notable results.
- Both Taiwan injectable facility and Changshu API plant underwent FDA inspections, both successfully passed with zero deficiencies
- Taiwan API plant underwent ANIVSA 1st inspections and passed with zero deficiencies, a milestone achieved for product expansion to South America market.

II. Accelerate approval for proprietary finished dosage products in high-growth sizable disease areas

- Proprietary Drug Products
  - Focus on high growth disease areas with pressing unmet medical needs: Metabolic (Diabetes+Obesity), Cancer, CNS diseases
  - Comprehensive and robust pipeline on GLP-1 peptide products in both diabetes and obesity to capture short-term, mid-term and long-term growth.
  - Proactively expand beyond US market to capture growth in Europe and Asian countries.
- 505(b)(2) Products
  - Leverage strategic partnerships to co-develop 505(b)(2) projects
  - Strengthen pipeline with both injectable and oral formulation capabilities
- API products
  - Develop high growth main-stay oncology targeted therapy drugs
  - Hold core position in value chain

III. Expand CDMO services to capture next wave of innovation ; And maximize GMP facility assets return

- ScinoPharm has built expertise in complex peptide injectable products, small molecule hi-potency environment management, world-class quality assurance system. These are highly sought after capabilities by drug developers.
- ScinoPharm will actively provide valuable services to drug innovators, big or small, to accelerate drug development, maximize ScinoPharm assets value, and stay at the frontier of drug industry value creation.



Business Update and Outlook

Strengthening API Business

- 77 generic APIs developed and DMF submitted, of which 37 products being supplied to customers for commercial selling in the market, and continue to support customers' registration as well as commercial launch
- Maintain existing market share, and proactively work with customers to enter into new markets, such as China, Europe, and South America, to expand our global presence
- Keep developing new generic APIs to enrich our pipeline, currently 12 new APIs being developed



Accelerating Drug Product Business Development

- Continuously expanding injectable drug product portfolio, and accelerate the approval of proprietary injectable products in US, aligning with our goal of providing vertical integration from API development to finished dosage forms
- Proactively expand beyond US market to capture growth in other countries such as Canada, Australia, Japan, China, Europe, etc.

Dosage Form	Project Numbers	Indication	Under Development	Technical Package Ready	Dossier Ready	Under Registration	Approved
Lyophilized Powder	4	• Myelodysplastic Syndromes • Multiple Myeloma • Oncology		1 1			1 1
Liquid Solution	6	• Leukemia • Oncology • Reversal of Neuromuscular Blockade		 4 1			1
Prefilled Syringe	3	• Thromboembolic Disorders • Multiple Sclerosis • Medical Imaging Agents		 1		1#	1
Cartridge in Device	5	• Osteoporosis • Diabetes Mellitus • Chronic Weight Management	1	1	 1	1* 1*	

Responded to FDA CRL / * Preparing for response to FDA CRL

Expanding CDMO Services

- **Focus on specialized areas such as peptides, steroids, and cytotoxic products, and expand our global presence in CDMO sector**
- **With the development & production capabilities both in APIs and injectables DPs, value up our services to provide total solution to drug innovation companies**
- **With excellent manufacturing capabilities, proactively grab the contract manufacturing opportunities from global pharmaceutical companies for both APIs and injectables DPs**



- **2024 : 1 NDA of customer's product was approved, and 1 product's business status progressed from pre-clinical to Phase II**
- **2025 : 3 NDAs of customer's product expected to be approved in 2025**

Developing China Business Actively

- Leveraging the strengths of our Tainan and Changshu facilities, now entering a growth phase in China market
- Continue expanding customer base for the approved APIs, of which olaparib was launched in China market by customer after CDFI approval in 2024, and plan for regulatory submissions of more generic APIs in China plus aggressively develop CDMO services in 2025
- In 2024, ScinoPharm Changshu maintained its profitability, and passed GMP inspections by China authority for totally five products up-to-date with the products being commercially supplied to customers, anticipate on a continued growth trajectory onward for ScinoPharm Changshu
- ScinoPharm Changshu continues to develop new APIs products to enrich product pipeline, and also deepen collaborations with Chinese pharmaceutical companies, targeting not only China but also international markets

* Source：IQVIA Data (2023Q3-2024Q2)



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	2024		YoY	2023	
Revenue	3,406	100%	7%	3,186	100%
Gross Profit	1,300	38%	7%	1,216	38%
Operating Expenses	(979)	(29%)	9%	(902)	(28%)
Operating Profit	321	9%	2%	314	10%
Net Profit before Tax	413	12%	18%	349	11%
Net Profit after Tax	339	10%	18%	287	9%
EPS (NTD)	0.43	-	-	0.36	-

Sales Distribution – By Business





Note：Starting from 2024, statistics will be listed using a new classification method

Unit: USD/M

	API	CDMO	Drug Product
FY 2024 Sales	74.4	30.7	1.0
YoY	0.6%	15.1%	-32.7%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
FY 2024 Sales	65.5	26.0	14.6
YoY	3.2%	17.6%	-11.7%

Consolidated Balance Sheet

NTD Million	2024/12/31		2023/12/31	
Cash and Cash Equivalents	4,166	35%	3,942	33%
Accounts Receivable	604	5%	788	7%
Inventories	1,673	14%	1,511	13%
Property, Plant & Equipment	3,739	32%	3,763	32%
Other Current/Non-Current Assets	1,761	14%	1,717	15%
Total Assets	**11,943**	**100%**	**11,721**	**100%**
Financial Debt	36	0%	32	0%
Other Current Liabilities	732	6%	697	6%
Other Non-Current Liabilities	649	6%	628	6%
Total Liabilities	**1,417**	**12%**	**1,357**	**12%**
Total Shareholders' Equities	**10,526**	**88%**	**10,364**	**88%**

Consolidated Cash Flow Statement

NTD million	2024	2023	Dif.
From Operating Activities	**751**	**231**	**520**
Depreciation & Amortization	488	461	27
From Investing Activities	**(293)**	**(233)**	**-60**
Capital Expenditure	(300)	(285)	-15
From Financing Activities	**(245)**	**(341)**	**96**
Effect of foreign exchange rate changes	**11**	**(10)**	**22**
Net Change in Cash	**224**	**(353)**	**577**
Beginning Balance	**3,942**	**4,295**	**-353**
Ending Balance	**4,166**	**3,942**	**224**



Q & A

Appendix
Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 77 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 958 active DMFs worldwide with 67 US DMFs*
- 200+ contract projects with 14 approved/launched (12 NCEs) and 4 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority. In November 2024, we passed Brazilian ANVISA 1st on-site GMP inspection with zero defect and maintained its exceptional track record of 5 consecutive zero defect inspections by the US FDA
- Injectable plant certified by US FDA and TFDA

*Data As of 2025/01/31

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT